U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are require

	Substitute for form 1449/PTO				Complete if Known			
	INEO	DRANTIC	N DIC	01.00115=	Application Number	10/712,795	_	
				CLOSURE	Filing Date	11/13/2003		
STATEMENT BY APPLICANT				PPLICANT	First Named Inventor	Rosanne M. Crooke	_	
	(Use as many sheets as necessary)				Art Unit	1633	_	
_		(Use as man	y sheets as	necessary)	Examiner Name	Janet L. Epps-Ford		
	Sheet	1	of	2	Attorney Docket Number	DOC-0216US		

U.S. PATENT DOCUMENTS						
Examiner	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		
Initials *		Number - Kind Code <sup>2</sup> (if known)			Pages, Columns, Lines, Where Relevar Passages or Relevant	
/JE/	DE	US-5,801,154	09-01-1998	Baracchini et al.	Figures Appear	
/JE/	DF	US-6,512,161	01-28-2003	Rouy et al.		
	·			<del></del>	·	
					,4	
			<del></del>			

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines,	
Initials*	No.1	Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)			Where Relevant Passages or Relevant Figures Appear	T⁰
/JE/	DH	WO 00/00504 A1	01-06-2000	Isis Pharm.		
/JE/	DI	WO 03/011887 A2	02-13-2003	Isis Pharm.	f	
/JE/	DJ	WO 03/074723 A2	09-12-2003	Dhallan		
				<del></del>		
			<del></del>			
						<del></del>
						··
				-		

Examiner Signature	/Janet Epps Ford/	Date Considered	07/19/2007
-----------------------	-------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete to comple

Approved for use through 09/30/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

**DOC-0216US** 

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449/PTO Complete if Known Application Number 10/712,795 INFORMATION DISCLOSURE Filing Date 11/13/2003 STATEMENT BY APPLICANT First Named Inventor Rosanne M. Crooke Art Unit (Use as many sheets as necessary) Examiner Name Janet L. Epps-Ford

Attorney Docket Number

Sheet

of 2

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  AGRAWAL, S. et al., "Antisense therapeutics: is it as simple as complementary base recognition?" Mol. Med. Today (2000) 6:72-81.			
/JE/	DK				
DL DM		CROOKE, S. T., "Basic Principles of Antisense Therapeutics," Antisense Research and Application (1998) Springer-Verlag Press, Berlin, pp 1-50.			
		EMBL Accession No. L27195, January 6, 1994.			
	DN	GRAHAM, M. J. et al., "Inhibition of ApoB-100 as a Therapeutic Strategy for the Treatment of Hyperlipidemias," AHA Abstracts (2002).			
	DO	HUANG, LS. et al., "Hypobetalipoproteinemia Due to an Apolipoprotein B Gene Exon 21 Deletion Derived by Alu-Alu Recombination," J. Biol. Chem. (1969) 264(19):11394-11400.			
	DP	JEN, KY. et al., "Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," Stem Cells (2000) 18:307-319.			
	DQ	LATORRA, D. et al., "Enhanced Allele-Specific PCR Discrimination in SNP Genotyping Using 3' Locked Nucleic Acid (LNA) Primers," <i>Hum. Mutat.</i> (2003) 22:79-85.			
	DR	MA, D. D. F. et al., "Synthetic oligonucleotides as therapeutics: the coming of age," <i>Biotech. Ann. Rev.</i> (2000) 5:155-196.			
	DS	NOWAK-GÖTTL, U. et al., "Lipoprotein (a): Its Role in Childhood Thromboembolism," Pediatrics (1997) 99(6):1-3.			
	DT	ROSSI, J. J. et al., "Introductory Remarks on the General Application of Antisense RNAs and Ribozymes," <i>Methods Enzym.</i> (1993) 5:1-5.			
	DU	SKRAPARI, L. et al., "Glibenclamide improves postprandial hypertriglyceridaemia in Type 2 diabetic patients by reducing chylomicrons but not the very low-density lipoprotein subfraction levels," <i>Diabetic Med.</i> (2001) 18:781-785.			
/JE/	DV	TANAKA, M et al. "Regulation of Apolipoprotein B Production and Secretion in Response to the Change of Intracellular Cholesteryl Ester Contents in Rabbit Hepatocytes," J. Biol. Chem. (1993) 268(17):12713-12718.			

Examiner Signature	/Janet Epps Ford/	Date Considered	07/19/2007

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of Information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.